Charles River Laboratories (CRL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Charles River Laboratories stock (CRL) is currently trading at $165.89. Charles River Laboratories PS ratio (Price-to-Sales) is 1.95. Analyst consensus price target for CRL is $197.47. WallStSmart rates CRL as Sell.
- CRL PE ratio analysis and historical PE chart
- CRL PS ratio (Price-to-Sales) history and trend
- CRL intrinsic value — DCF, Graham Number, EPV models
- CRL stock price prediction 2025 2026 2027 2028 2029 2030
- CRL fair value vs current price
- CRL insider transactions and insider buying
- Is CRL undervalued or overvalued?
- Charles River Laboratories financial analysis — revenue, earnings, cash flow
- CRL Piotroski F-Score and Altman Z-Score
- CRL analyst price target and Smart Rating
Charles River Laboratories
📊 No data available
Try selecting a different time range
Smart Analysis
Charles River Laboratories (CRL) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Charles River Laboratories (CRL) Key Strengths (4)
Growing significantly faster than its price suggests
110.23% of shares held by major funds and institutions
Paying $1.95 for every $1 of annual revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Charles River Laboratories (CRL) Areas to Watch (6)
Company is destroying shareholder value
Revenue declining -0.80%, a shrinking business
Earnings declining -17.30%, profits shrinking
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Fairly priced relative to book value
Charles River Laboratories (CRL) Detailed Analysis Report
Overall Assessment
This company scores 41/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Price/Sales. Valuation metrics including PEG Ratio (0.12), Price/Sales (1.95) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, EPS Growth. Some valuation metrics including Price/Book (2.39) suggest expensive pricing. Growth concerns include Revenue Growth at -0.80%, EPS Growth at -17.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -4.23%, Operating Margin at 4.51%, Profit Margin at -3.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -4.23% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRL's Price-to-Sales ratio of 1.95x sits near its historical average of 2.2x (40th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 45% below its historical high of 3.57x set in Nov 2018, and 119% above its historical low of 0.89x in Jan 2009. Over the past 12 months, the PS ratio has compressed from ~2.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Charles River Laboratories (CRL) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Charles River Laboratories is in a turnaround phase, with management focused on restoring profitability. Revenue reached 4.0B with 1% decline year-over-year. The company is currently unprofitable, posting a -3.6% profit margin.
Key Findings
Generating 59M in free cash flow and 148M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -3.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.65, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Charles River Laboratories.
Bottom Line
Charles River Laboratories is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Charles River Laboratories(CRL)
NYSE
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.